KUALA LUMPUR, April 6, 2017 ¬– Pharmaniaga Berhad (Pharmaniaga) successfully weathered through a challenging year, recording satisfactory results despite tough market conditions. The Group remains committed to tapping into the inherent potential of the healthcare industry, both in Malaysia and globally.
For its financial year ended 31 December 2016, the Group posted a profit after tax of RM46 million. Profit before tax came in at RM72 million while revenue stood at RM2.2 billion.
As a reflection of its commitment to delivering value to shareholders, the Group declared total dividends of 16 sen per share for the year. This represents a dividend yield of 3% and a total dividend payout of RM41.5 million.
YBhg Tan Sri Dato’ Seri Lodin Wok Kamaruddin, Chairman, Pharmaniaga Berhad, commented after the Annual General Meeting, “Despite subdued market sentiment, the Group was able to clock in positive results. While the Government businesses were impacted by lower orders, this was moderated by encouraging growth in our Indonesian operations and private sector business.”
“Moving forward, the outlook remains bright for the healthcare industry and Pharmaniaga is well-positioned to capitalise on this over the long-term. Towards this end, we aim to expand our product portfolio in order to further reinforce our position as a leading generics medicines manufacturer in the marketplace. At the same time, we are firmly committed to delivering the highest standards of excellence to meet the needs of all our clientele, particularly the Ministry of Health.”
“In our overseas operations, we are focused on expanding our presence in Indonesia, which is an exciting market for the Group given the strong prospects in the country. In tandem with this, we will continue to enhance operational efficiencies across the Group.”
“With these strategic plans in place, we are confident that we will be able to remain resilient and drive the Group forward in the year ahead,” concluded YBhg Tan Sri Dato’ Seri Lodin.
Forward looking statements
This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.